The global neuroscience market size was estimated at USD 42.5 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.56% from 2023 to 2030. This can be attributed to the increasing prevalence of neurological diseases, such as Alzheimer’s, brain cancer, epilepsy, and traumatic brain injuries. According to Alzheimer's Association, approximately 6 million American individuals suffer from Alzheimer's, which is anticipated to rise to 13 million by 2050. Furthermore, the progression of the neuroscience field has been driven by the emergence of advanced technological abilities, and the speed at which these R&D capabilities are being developed has accelerated significantly in recent years.
For instance, the U.S. launched the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) program for research and development of novel investigational methods that will enhance the understanding of the brain. Such initiatives will channel the knowledge into innovative solutions for diagnosing and treating neurological patients. In addition, increasing healthcare digitalization improves the management of neurological disorders, which, in turn, is expected to propel the adoption of advanced neuroscience devices over the forecast period. For instance, in May 2023, Australian researchers Dr. Thomas Oxley and Nicholas Opie developed a human-brain-computer interface system that conveys data from the patient’s brain remotely to control external digital devices helping severely paralyzed patients in communicating using their thoughts.
Such inventions help open new opportunities in the neuroscience field. Moreover, the rising awareness among the global population about neurological disease diagnosis and their treatment options is expected to positively contribute to market growth. For instance, the American Academy of Neurology runs Neuroscience Is. initiatives to build public awareness about neurological disorders and demonstrate the importance of neuroscience research in treating neurology patients and developing a treatment for brain-associated diseases. The COVID-19 pandemic had a high impact on the market. Many neurological device manufacturing companies witnessed a decline in sales revenue during the COVID-19 pandemic. This was driven by declines in neurosurgery, partially offset by strength in neurovascular. In addition, strict regulations undertaken by the government, such as nationwide lockdowns and supply chain breakdown, led to a shortage of neurological devices and consumables globally.
Based on components, the market has been segmented into instruments, consumables, and software & services. The instrument segment accounted for the largest share of 64.71% in 2022. This can be attributed to the launch of new instrument devices for diagnosing and treating neurological disorders. In May 2023, Koninklijke Philips N.V. launched an AI-powered CT system, the Philips CT 3500, to perform routine radiology and high-volume screening programs. This device can deliver high-quality images required by radiologists to make precise diagnoses.
The consumables segment is also expected to witness significant growth during the forecast period. Key players, such as B. Braun SE and GE HealthCare, offer strong, durable, easy-to-handle consumables of neurological instruments. These consumables include ScalpFix Clips, Flat Table Tops, patient monitors, injectors, head holder inserts, cradle pads, and others. The development and introduction of new consumables further contribute to segment growth.
Based on technology, the neuroscience industry has been segmented into brain imaging, neuro-microscopy, stereotaxic surgeries, neuro-proteomic analysis, neuro-cellular manipulation, and others. The brain imaging segment accounted for the largest share of 25.19% in 2022. This can be attributed to the increased use of brain imaging devices, such as MRI, EEG, and CT scans, in hospitals, diagnostic centers, and ambulatory surgical centers (ASCs) to diagnose neurological diseases. As per NHS England and NHS Improvement Report 2022, approximately 67,215 people were referred for brain MRI scans by physicians in March 2022 for diagnosing cancer.
Thus, the increasing adoption of brain imaging has spurred the demand for imaging devices in the coming years. The neuro-microscopy segment is also expected to witness significant growth during the forecast period owing to advancements in neuro-microscopy. In May 2023, Deblina Sarkar, a nanotechnologist and assistant professor at MIT, announced the development of ultra-tiny electronic microscopic miniature machines, which can enter the brain, and detect and reverse neurological disorders. Furthermore, the presence of key companies, such as Danaher Corporation and Carl Zeiss AG, and their wide neuro-microscopy offerings are projected to propel segment growth during the forecast period.
Based on end-user, the market has been segmented into hospitals, diagnostic laboratories, and research & academic institutes. The diagnostic laboratories segment accounted for the largest revenue share of 42.04% in 2022. This can be attributed to the wide application scope of neurological devices in diagnostic laboratories and increased awareness among the population about early disease diagnosis benefits. According to Parkinson's Foundation, more than 90,000 people have been diagnosed with Parkinson’s disease each year. Some of the widely used neurological devices in diagnostic centers for diagnosis purposes are CT scans, MRIs, electroencephalograms (EEG), electromyograms (EMG), and others.
Thus, introducing safe, durable, and effective neurological devices is anticipated to drive the industry's growth. The hospital segment is expected to witness the fastest growth rate during the forecast period owing to the increasing hospitalization of patients with neurological disease conditions. According to the National Center for Biotechnology Information (NCBI), each year, 22.6 million people suffer from neurological injuries or disorders, of whom 13.8 million require surgical treatment. Thus, the increasing number of neurological hospital admissions boosts the demand for devices required for surgery, thereby driving segment growth.
Based on region, North America accounted for the largest market share of 31.42% in 2022. This can be attributed to the strong presence of companies engaged in developing, manufacturing, and commercializing devices used for diagnosing and treating neurological patients in the region. For instance, in February 2022, CERENOVUS launched an advanced balloon guide catheter, EMBOGUARD, to be used in endovascular procedures, especially in patients with acute ischemic stroke. The Asia Pacific region is expected to witness the fastest growth during the forecast period.
This can be attributed to growing investments in healthcare logistic infrastructure, with high healthcare spending contributing to the growth of the neuroscience industry. In September 2022, the Government of China introduced its “China Brain Project (CBP)” with a starting investment of USD 746 million, intending to focus on areas of the neural basis of cognitive functions, brain-inspired computing, and diagnosing and treating brain disorders. Such initiatives from public bodies are anticipated to boost R&D in neuroscience, thereby driving market growth.
Strategic partnerships, major R&D investments, and the development of new products or product modifications are among the key strategies adopted by companies to gain a competitive edge in the market. In May 2023, the U.S. Food and Drug Administration (FDA) granted clearance to an artificial intelligence (AI) software, Neurophet AQUA, to improve the assessment of brain atrophy on the MRI. This launch will help physicians in providing the right treatment course to patients and improve brain monitoring. Some of the prominent players in the global neuroscience market include:
Carl Zeiss AG
Danaher Corporation
GE Healthcare
Siemens Healthcare Private Limited
Koninklijke Philips N.V.
Canon Inc.
B. Braun SE
Medtronic
Stryker
Boston Scientific Corporation
ABBOTT
Terumo Corporation
Report Attribute |
Details |
Market size value in 2023 |
USD 44.6 billion |
Revenue forecast in 2030 |
USD 65.2 billion |
Growth rate |
CAGR of 5.56% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Report updated |
August 2023 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Component, technology, end-user, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; India; Japan; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Carl Zeiss AG; Danaher Corp.; GE Healthcare; Siemens Healthcare Private Limited; Koninklijke Philips N.V.; Canon Inc.; B. Braun SE; Medtronic; Stryker; Boston Scientific Corp.; ABBOTT; Terumo Corp. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the neuroscience market report on the basis of component, technology, end-user, and region:
Component Outlook (Revenue, USD Million, 2018 - 2030)
Instruments
Consumables
Software & Services
Technology Outlook (Revenue, USD Million, 2018 - 2030)
Brain Imaging
Neuro-Microscopy
Stereotaxic Surgeries
Neuro-Proteomic Analysis
Neuro-Cellular Manipulation
Others
End-user Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Diagnostic laboratories
Research and Academic Institute
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global neuroscience market size was estimated at USD 42.5 billion in 2022 and is expected to reach USD 44.6 billion in 2023.
b. The global neuroscience market is expected to grow at a compound annual growth rate of 5.56% from 2023 to 2030 to reach USD 65.2 billion by 2030.
b. Brain imaging dominated the neuroscience market with a share of 25.1% in 2022. This is attributable to a substantial number of applications in neuroscience-based research wherein imaging techniques are employed.
b. Some key players operating in the neuroscience market include Carl Zeiss AG; Danaher Corporation; GE Healthcare ; Siemens Healthcare Private Limited; Koninklijke Philips N.V.; Canon Inc.; B. Braun SE; Medtronic; Stryker ; Boston Scientific Corporation ; ABBOTT; Terumo Corporation
b. Key factors that are driving the market growth include ongoing brain mapping research & investigation projects; neuroscience-based initiatives by government bodies; and technological advances in tools & algorithms that are implemented in neuroscience space.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."